New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis

  • Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
  • 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
  • New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
/by

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis

  • Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented
  • 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured
  • New insights into disease characteristics in IgAN and C3G inform future research and treatment approaches
/by